3D Epidermis Model for Cancer Drug Skin Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Oncology treatments, particularly kinase inhibitors, often cause Cutaneous Adverse Drug Reactions (CADRs) in patients, leading to skin-related side effects that disrupt treatment protocols and significantly impact quality of life, despite their effectiveness in targeting proliferative cells.
Innovation Solution
A 3D micro-epidermis tissue culture model is used to assess the effects of Epidermal Growth Factor Receptor inhibitors (EGFRi) and Vascular Endothelial Growth Factor Receptor inhibitors (VEGFRi) on keratinocyte proliferation and differentiation, providing insights into skin barrier impairment and the development of therapeutic solutions to mitigate these adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If kinase inhibitors are used to target proliferative cells in cancer therapy, then tumor cell proliferation is inhibited, but skin barrier function is impaired and cutaneous adverse reactions occur
Solution Approach 1:
The patent introduces a protective composition containing ceramides, cholesterol, and free fatty acids as an intermediary substance that mediates between the kinase inhibitor therapy and the skin barrier. This composition is applied topically to the skin to protect keratinocytes from the harmful effects of the systemic cancer therapy while allowing the therapy to continue systemically. The protective composition acts as a local buffer that mitigates the adverse effects without interfering with the systemic anticancer activity.
Solution Approach 2:
The patent applies protective skin compositions containing specific lipid components (ceramides, cholesterol, free fatty acids) before or during kinase inhibitor therapy to preemptively protect the skin barrier. By establishing this protective barrier in advance, the skin is pre-conditioned to resist the harmful effects of the kinase inhibitors, preventing cutaneous adverse reactions before they occur rather than treating them after manifestation.
2Reliability
If kinase inhibitors are administered to patients, then cancer cell growth is suppressed, but keratinocyte proliferation and differentiation are disrupted
Solution Approach 1:
The protective composition serves as an intermediary that delivers essential lipid components (ceramides, cholesterol, free fatty acids) directly to the skin, compensating for the disruption caused by kinase inhibitors. These lipids are crucial for maintaining keratinocyte differentiation and skin barrier structure, and their topical application restores the biochemical environment needed for stable keratinocyte function without interfering with the systemic kinase inhibitor action on cancer cells.
Solution Approach 2:
The patent changes the local biochemical parameters of the skin by applying a composition with specific lipid ratios (ceramides, cholesterol, free fatty acids) that counteracts the parameter changes induced by kinase inhibitors. By modifying the local lipid composition and concentration in the skin, the patent restores keratinocyte differentiation stability while maintaining the systemic pharmacological effect of the kinase inhibitors on cancer cells.
3Object-affected harmful factors
If skin barrier function is supported during therapy, then cutaneous adverse reactions are reduced, but treatment protocol complexity increases
Solution Approach 1:
The patent segments the treatment protocol into two independent components: systemic kinase inhibitor therapy for cancer and topical protective composition application for skin protection. This segmentation allows each component to be optimized independently - the systemic therapy targets cancer cells while the topical application addresses skin protection. The two can be administered separately with different frequencies and formulations, reducing the complexity of managing a single integrated protocol.
Solution Approach 2:
The protective skin composition acts as an intermediary layer that simplifies the overall treatment approach by providing a straightforward topical application that addresses multiple skin-related adverse reactions simultaneously. Rather than requiring complex monitoring and intervention for each type of cutaneous adverse reaction, the single protective composition provides comprehensive skin protection, reducing the complexity of treatment management.
Data Source
AI summary
An epidermal tridimensional model exhibiting differentiating keratinocytes in a reconstituted stratum corneum model is disclosed. The model, which contains a cancer therapeutic at an amount effective to simulate chronic drug exposure, can be used to evaluate the potential of cancer therapeutics to produce skin related side effects. The method can also be used to evaluate the efficacy of a composition in reducing the effects of cancer therapeutics on skin.